Adenosine Receptors: The A_2B-Receptor Target

The Science of the A_2B-receptor

In chronic lung diseases, such as asthma, stimulation of the adenosine
A_2B-receptor in the lungs may initiate damaging inflammatory processes. Scientists at CV Therapeutics believe that selective blockade of this signaling pathway may one day lead to a novel therapeutic approach.

In asthma, chronic inflammation of the airways is associated with an increase in airway hyperresponsiveness. Recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning, may result and are usually reversible either spontaneously or with treatment.

High levels of adenosine are generated in areas of lung tissue inflammation, offering a possible target for the exploration of future therapies.